Skip to main content
ALIVUS LIFE SCIENCES LIMITED logo

ALIVUS LIFE SCIENCES LIMITED — Investor Relations & Filings

Ticker · ALIVUS ISIN · INE03Q201024 LEI · 335800RYVA1DKP696G32 BSE.NS Manufacturing
Open in API
Filings indexed 352 across all filing types
Latest filing 2026-01-22 Investor Presentation
Country IN India
Listing BSE.NS ALIVUS

About ALIVUS LIFE SCIENCES LIMITED

https://www.alivus.com

Alivus Life Sciences Limited is a pharmaceutical organization dedicated to the formulation, production, and commercialization of a broad spectrum of healthcare solutions. The company operates across multiple therapeutic categories, including gastroenterology, anti-infectives, pain management, and nutritional supplements. Its product range includes diverse delivery formats such as tablets, capsules, syrups, and injectable medications. Alivus Life Sciences focuses on maintaining rigorous quality control protocols and manufacturing excellence to deliver reliable therapeutic outcomes. The company utilizes a robust distribution infrastructure to supply its pharmaceutical products to healthcare providers and patients, prioritizing the accessibility of essential medicines and the continuous expansion of its therapeutic portfolio.

Recent filings

Filing Released Lang Actions
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation – Q3 FY 25-26' and is addressed to stock exchanges referencing regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, which mandates disclosure of material events including investor presentations. The content includes detailed financial performance data for Q3 and 9 months FY26, segmental performance, market mix, and business outlook. It is a presentation document intended for investors, containing forward-looking statements and detailed financial highlights but not a formal quarterly report or earnings release. The document length is substantial (15,000 characters), indicating it is the full presentation, not just an announcement. Therefore, the document fits the category of an Investor Presentation (IP).
2026-01-22 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release announcing the unaudited financial results for the third quarter and nine months ended December 31, 2025. It contains key financial highlights such as revenue, EBITDA, PAT, margins, and cash flow figures, along with management commentary. The document is dated January 22, 2026, and references quarterly and nine-month periods, indicating it is a quarterly earnings announcement. It is not a full interim report with detailed financial statements, but rather a summary of financial performance and operational highlights. Therefore, it fits the definition of an Earnings Release (ER). The document length (7139 characters) and content support this classification with high confidence. 9M 2026
2026-01-22 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a letter to the stock exchanges under SEBI LODR regulations announcing and enclosing the unaudited financial results for the third quarter and nine months ended December 31, 2025. It contains full interim financial statements (income, expenses, comprehensive income, earnings per share, notes prepared under Ind AS 34) rather than just key highlights. This fits the definition of an Interim/Quarterly Report (Code: IR). 9M 2026
2026-01-22 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 95% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) informing about the allotment of equity shares under the Employee Stock Option Scheme, 2021. It details the number of shares allotted and the consequent increase in paid-up share capital. There is no financial statement, earnings data, or detailed report content. The document is an announcement of a capital change due to share allotment under an ESOP scheme. It fits the category of Share Issue/Capital Change announcements rather than a full report or regulatory filing. The document length is short and focused solely on the share allotment event.
2026-01-21 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 75% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) providing details about an upcoming earnings call scheduled for January 22, 2026. It includes dial-in numbers and contact information for clarifications. The document does not contain any financial data or results itself, but rather is an announcement or invitation to the earnings call event. The length is short (2348 characters), and it serves as a notification rather than a report or transcript. Therefore, it fits the category of a Call Transcript (CT) announcement or invitation, but since it is not the transcript itself, it is best classified as a Regulatory Filing (RNS) as a general announcement. However, given the specific nature of the document as an earnings call invitation, the most appropriate classification is Call Transcript (CT) with moderate confidence, as it is related to the earnings call event but not the transcript itself.
2026-01-15 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2026-01-14 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.